A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

NCT00517699 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated early due to lack of enrollment.

Conditions

Lymphoma

Interventions

DRUG: rituximab [MabThera/Rituxan]
DRUG: Methotrexate
DRUG: Cytarabine

Sponsor

Hoffmann-La Roche